| Michael Allen Lenzner, RPH | |
|
2160 Coast Ave, San Marcos, CA 92078-8401 | |
| (800) 914-8771 | |
| (800) 914-8772 |
| Full Name | Michael Allen Lenzner |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 2160 Coast Ave, San Marcos, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013230655 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH33245 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Allen Lenzner, RPH 2160 Coast Ave, San Marcos, CA 92078-8401 Ph: (800) 914-8771 | Michael Allen Lenzner, RPH 2160 Coast Ave, San Marcos, CA 92078-8401 Ph: (800) 914-8771 |
News Archive
A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).
The study, published in Clinical Cancer Research, has proved for the first time that the targeted use of an anti-oestrogen drug could prolong the life of some patients by up to three years, and delay the use of chemotherapy in others.
Tyler Wertz, 18, and his 16-year old brother Austin Tucker, fight, tease, love and support each other like most brothers do. Unlike most brothers, however, they share the same uncertain future—both have heart assist devices keeping them alive while they struggle with a debilitating disease. As young boys, Tyler and Austin were diagnosed with Becker's Muscular Dystrophy, a disease that slowly weakens the arms and legs and damages the heart.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.
Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.
› Verified 7 days ago
Sonal Kirti Patel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 416 Camino Hermoso, San Marcos, CA 92078 Phone: 949-379-4022 | |
Amy Dollbaum, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 725 Center Dr, San Marcos, CA 92069 Phone: 760-871-6868 Fax: 760-871-6869 | |
Dr. Rose Ridings Feaver, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 Craven Rd, San Marcos, CA 92078 Phone: 760-510-4077 Fax: 760-510-4450 | |
Evelyn Kwan, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 191 Woodland Pkwy, San Marcos, CA 92069 Phone: 760-471-9007 Fax: 760-471-9785 | |
Minh Truong, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 320 S Twin Oaks Valley Rd, San Marcos, CA 92078 Phone: 760-741-8014 | |
Lena Hanhduyen Pham, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 191 Woodland Pkwy, San Marcos, CA 92069 Phone: 760-471-9007 Fax: 760-471-9785 |